Literature DB >> 3937269

Postoperative changes in the plasmatic levels of tissue-type plasminogen activator and its fast-acting inhibitor--relationship to deep vein thrombosis and influence of prophylaxis.

J A Páramo, M J Alfaro, E Rocha.   

Abstract

Fibrinogen, euglobulin lysis time (ELT), tissue-type plasminogen activator (t-PA) antigen, plasminogen activator inhibitor activity (PA-inhibitor) and alpha 2-antiplasmin (alpha 2-AP) were measured pre- and postoperatively in 60 patients undergoing total hip replacement. Reduced fibrinolytic activity as assessed by the prolongation of euglobulin lysis time, decrease of t-PA and increase of PA-inhibitor and alpha 2-AP could be demonstrated. These changes did not correlate with the postoperative deep vein thrombosis (DVT) diagnosed with the 125I-fibrinogen test. However, preoperative PA-inhibitor activity was significantly higher in patients with postoperative DVT (p less than 0.01). The prophylactic treatment with aspirin (20 patients) and with heparin plus dihydroergotamine (20 patients) induced significant changes in some of those parameters. This study shows that the decrease of t-PA and the increase of PA-inhibitor may contribute to the reduced postoperative fibrinolytic activity after total hip replacement. PA-inhibitor level might be a useful marker in evaluating the risk of developing DVT in patients undergoing total hip replacement.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3937269

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  15 in total

Review 1.  A guide to venous thromboembolism risk factor assessment.

Authors:  G D Motykie; L P Zebala; J A Caprini; C E Lee; J I Arcelus; J J Reyna; E B Cohen
Journal:  J Thromb Thrombolysis       Date:  2000-04       Impact factor: 2.300

Review 2.  Fibrinolysis Shutdown in Trauma: Historical Review and Clinical Implications.

Authors:  Hunter B Moore; Ernest E Moore; Matthew D Neal; Forest R Sheppard; Lucy Z Kornblith; Dominik F Draxler; Mark Walsh; Robert L Medcalf; Mitch J Cohen; Bryan A Cotton; Scott G Thomas; Christine M Leeper; Barbara A Gaines; Angela Sauaia
Journal:  Anesth Analg       Date:  2019-09       Impact factor: 5.108

3.  Tissue plasminogen activator inhibitor in patients with systemic lupus erythematosus and thrombosis.

Authors:  F Violi; D Ferro; G Valesini; C Quintarelli; M Saliola; M A Grandilli; F Balsano
Journal:  BMJ       Date:  1990-04-28

4.  Amorphous calcium phosphate-mediated binding of matrix metalloproteinase-9 to fibrin is inhibited by pyrophosphate and bisphosphonate.

Authors:  G S Makowski; M L Ramsby
Journal:  Inflammation       Date:  1999-08       Impact factor: 4.092

Review 5.  Plasminogen activator inhibitor type-1 (part one): basic mechanisms, regulation, and role for thromboembolic disease.

Authors:  K Huber
Journal:  J Thromb Thrombolysis       Date:  2001-05       Impact factor: 2.300

Review 6.  Tissue-type plasminogen activator. A review of its pharmacology and therapeutic use as a thrombolytic agent.

Authors:  D Collen; H R Lijnen; P A Todd; K L Goa
Journal:  Drugs       Date:  1989-09       Impact factor: 9.546

7.  Postoperative venous thromboembolism and brain tumors: Part II. Hemostatic profile.

Authors:  R Sawaya; P Glas-Greenwalt
Journal:  J Neurooncol       Date:  1992-10       Impact factor: 4.130

8.  Effect of oral defibrotide on tissue-plasminogen activator and tissue-plasminogen activator inhibitor balance.

Authors:  F Violi; D Ferro; M Saliola; C Quintarelli; S Basili; F Balsano
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

9.  Prothrombotic abnormalities in inflammatory bowel disease.

Authors:  M G Conlan; W D Haire; D A Burnett
Journal:  Dig Dis Sci       Date:  1989-07       Impact factor: 3.199

10.  Plasminogen activator inhibitor-1 (PAI-1) expression in relation to hypoxia and oncoproteins in clinical cervical tumors.

Authors:  P C Lara; M Lloret; A Valenciano; B Clavo; B Pinar; A Rey; L A Henríquez-Hernández
Journal:  Strahlenther Onkol       Date:  2012-11-01       Impact factor: 3.621

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.